中文名稱:Anisomycin | 英文名稱:Anisomycin |
CAS:22862-76-6 | 品牌: 一研 |
保存條件: Store at -20°C | 產(chǎn)品類別: 抑制劑 |
Cas : 22862-76-6 |
產(chǎn)品屬性:
產(chǎn)品名稱 | 規(guī)格 | CAS號(hào) | 型號(hào) |
Anisomycin | 10mM (in 1mL DMSO) 10mg 50mg 500mg 1g | 22862-76-6 | EY-Y0165156 |
Cas No.22862-76-6
別名 N/A
化學(xué)名 (2R,3S,4S)-4-hydroxy-2-(4-methoxybenzyl)pyrrolidin-3-yl acetate
分子式 C14H19NO4
分子量 265.31
溶解度 ≥ 26.5mg/mL in DMSO
儲(chǔ)存條件 Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產(chǎn)品描述:
Anisomycin is a specific agonist of JNK with a concentration of 25 ng/ml [1].
JNK is short for c-Jun N-terminal kinase which reported as a proapoptotic kinase and plays an important role in many cellular events, such as cell cycle, proliferation, apoptosis and cell stress. It is also reported that JNK plays a pivotal role in the cell apoptosis induced by UV and activated JNK pathway could enhance TNF-α mediated apoptosis thus often regarded as a potent target in clinic [2] [3].
Anisomycin is a potent JNK agonist. When tested with hormone refractory cell line DU 145(highly resist to Fas mediated apoptosis), 250 ng/ml anisomysin treatment induced DU145 cells apoptosis together with Fas (200 ng/ml) via activating JNK [4]. In HL-60 cells, treatment of anisomysin activated JNK pathway activity which further induced cell apoptosis [5]. When tested with primary murine embryonic fibroblasts, anisomycin treatment stimulated cell apoptosis via activating JNK expression [6].
References:
[1]. Jiang, J., et al., Spermassociated antigen 9 promotes astrocytoma cell invasion through the upregulation of podocalyxin. Mol Med Rep, 2014. 10(1): p. 417-22.
[2]. Lin, A., Activation of the JNK signaling pathway: breaking the brake on apoptosis. Bioessays, 2003. 25(1): p. 17-24.
[3]. Liu, J. and A. Lin, Role of JNK activation in apoptosis: a double-edged sword. Cell Res, 2005. 15(1): p. 36-42.
[4]. Curtin, J.F. and T.G. Cotter, Anisomycin activates JNK and sensitises DU 145 prostate carcinoma cells to Fas mediated apoptosis. Br J Cancer, 2002. 87(10): p. 1188-94.
[5]. Stadheim, T.A. and G.L. Kucera, c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for mitoxantrone- and anisomycin-induced apoptosis in HL-60 cells. Leuk Res, 2002. 26(1): p. 55-65.
[6]. Tournier, C., et al., Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science, 2000. 288(5467): p. 870-4.
成立日期 | 2014-06-05 (11年) | 注冊(cè)資本 | 100 |
員工人數(shù) | 50-100人 | 年?duì)I業(yè)額 | ¥ 100萬(wàn)以內(nèi) |
主營(yíng)行業(yè) | 生化試劑,抗體,細(xì)胞培養(yǎng),分子生物學(xué),免疫安全 | 經(jīng)營(yíng)模式 | 工廠,試劑 |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP5年
|
武漢鼎信通藥業(yè)有限公司
|
2025-02-08 | |
詢價(jià) |
VIP4年
|
四川省維克奇生物科技有限公司
|
2025-02-08 | |
詢價(jià) |
VIP9年
|
武漢維斯?fàn)柭锕こ逃邢薰?/div>
|
2025-02-08 | |
詢價(jià) |
VIP4年
|
江西瑞威爾生物科技有限公司
|
2025-02-08 | |
¥4785 |
VIP3年
|
湖北魏氏化學(xué)試劑股份有限公司
|
2025-02-08 | |
詢價(jià) |
VIP4年
|
江西瑞威爾生物科技有限公司
|
2025-02-08 | |
¥1700.00 |
VIP9年
|
湖北威德利化學(xué)科技有限公司
|
2025-02-08 | |
¥1500 |
VIP9年
|
武漢維斯?fàn)柭锕こ逃邢薰?/div>
|
2025-02-08 | |
¥529 |
VIP4年
|
湖北魏氏化學(xué)試劑股份有限公司
|
2025-02-08 | |
詢價(jià) |
VIP3年
|
湖北魏氏化學(xué)試劑股份有限公司
|
2025-02-08 |